PT - JOURNAL ARTICLE AU - Hazim Ghani AU - Liyana Ahmad AU - Hanisah Sharif AU - Justin Wong AU - Saifuddien Bagol AU - Mohammad Fathi Alikhan AU - Surita Taib AU - Chee Wah Tan AU - Feng Zhu AU - Xin Mei Ong AU - Chin Yee Shim AU - Yan Wang AU - Si Yee Chan AU - Yuan Wei AU - Fazean Idris AU - Lin Naing AU - Lin-Fa Wang AU - Anne Catherine Cunningham TI - Immunogenicity of COVID-19 vaccines and levels of SARS-CoV-2 neutralising antibody in the Bruneian population: Protocol for a national longitudinal study AID - 10.1136/bmjopen-2022-067020 DP - 2022 Dec 01 TA - BMJ Open PG - e067020 VI - 12 IP - 12 4099 - http://bmjopen.bmj.com/content/12/12/e067020.short 4100 - http://bmjopen.bmj.com/content/12/12/e067020.full SO - BMJ Open2022 Dec 01; 12 AB - Introduction Neutralising antibodies (NAbs) have been shown to be correlative of immune protection against SARS-CoV-2. We report the protocol for a national longitudinal study to assess and compare the level of NAbs generated in response to COVID-19 vaccines in Brunei Darussalam in adults 2–6 weeks post primary series (BBIBP-CorV, AZD1222, or mRNA-1273 vaccines) and their subsequent follow-up after administration of a third (booster-1) dose (BBIBP-CorV, mRNA-1273, or BNT162b2).Methods and analysis Participant data will be extracted and processed from the national electronic health record system (Bru-HIMS) and the national mobile health application (BruHealth) into a research data platform. Eligible adults who have received their primary or booster vaccine will be invited using a stratified random sampling strategy based on age, gender and vaccine type (baseline target population, n=3000; 2–6 weeks post last dose). Blood serum will be isolated, and NAb levels assessed using the cPass surrogate virus neutralisation test. Baseline participants will then be screened for eligibility for subsequent longitudinal analysis. Those who have received a third dose will be followed up at 1, 3, 6, 9 and up to 12 months. NAb levels will be evaluated across the participant population according to vaccine platform/booster type, time since the last dose and correlated with demographic data. The study period is from December 2021 to January 2023 and aims to evaluate how NAb levels wane following a third vaccine dose across different vaccine platforms and determine the impact and rate of breakthrough infections.Ethics and dissemination This study has been approved by the Medical and Ethical Research Committee of Ministry of Health, Brunei Darussalam. Individual NAb test results will be shared with each participant by text message. The findings from this study will help policy-makers in Brunei develop future vaccination strategies and establish regulations across multiple agencies.